Lustre Pharmaceutical Lab Co., Ltd Report issue

For profit Phase 4
Founded: Palanpur India (2001)
Status: No NME R&D (2001)

Organization Overview

First Clinical Trial
2014
NCT02269800
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (2)

benzyldodecyldimethylammonium chloride (2 trials)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases, Obstructive (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 2